Q4 2025 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2026-02-17 · accession 0001012975-26-000153
$651.7M
Reported value
9
Positions
2025-12-31
Period end
The Brief · ARCH Venture Management, LLC · Q4 2025
AI · grounded in 13F
ARCH Venture Management, LLC established a new position in 10X GENOMICS INC. TXG valued at $12.03M. The fund also closed its entire position in CERO THERAPEUTICS HOLDINGS INC. CERO, reducing exposure by $113,960. These moves leave the fund with 9 total positions and $651.68M in total assets under management.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 578784100 | MAZE | MAZE THERAPEUTICS INC. | $170.7M | 26.2% | 4,120,053 | Common | NONE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC. | $125.9M | 19.3% | 4,540,132 | Common | NONE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC. | $113.1M | 17.4% | 3,728,738 | Common | NONE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC. | $84.9M | 13.0% | 2,759,072 | Common | NONE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC. | $77.9M | 12.0% | 12,916,663 | Common | NONE |
| 29479A108 | ERAS | ERASCA INC. | $41.1M | 6.31% | 11,055,554 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO INC. | $25.0M | 3.83% | 8,055,916 | Common | NONE |
| 88025U109 | TXG | 10X GENOMICS INC. | $12.0M | 1.85% | 737,539 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC. | $1.1M | 0.16% | 320,482 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.